Insider Buying Activity Uncovered - 7 Stocks On The Rise

This is a must read. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Revolutionary Device Redefines Cancer Detection]( [Learn More Now - Before Anticipated FDA Approval in 2024]( --------------------------------------------------------------- April 02, 2024 Editorial Insights Insider trading occurs when company executives or major shareholders trade stocks based on non-public information. Monitoring these trades provides insight into insiders' expectations for the company's future. For instance, significant purchases before public announcements may indicate anticipated positive news and a potential share price increase. Note: "Insider Buying" is legal stock purchasing by company directors or officers, distinct from illegal insider trading based on non-public information. It's not a crime when based on public information. Insiders, having unique insights, often buy shares when they believe the stock is undervalued. This report lists stocks recently identified with substantial insider buying. --------------------------------------------------------------- Sponsor Message [Detecting Cancer in 1.5 Seconds: Early Investment Opportunity]( Stanford engineer's lofty goal of revolutionizing cancer diagnostics is expected to come to fruition with FDA review in its final stages. With a history of taking companies public, including a $2 billion market cap NASDAQ company, this may be his biggest venture yet! With the ability to detect cancer's "molecular fingerprint" in just 1.5 seconds, it also offers far superior accuracy to current detection methods! [Learn more about how this could transform the multi-billion dollar diagnostic market.]( --------------------------------------------------------------- [Reddit, Inc.]( Ticker: [RDDT]( Recent Price: $45.97 Average Analyst Price Target: $54.00 (17.47%) Market Cap: $7.46B Role Transaction Description No. of Shares Amount Date COO Informative Buy Non Open Market Buy 9,274 $426,347 Yesterday Recent Analyst Action: Daniel Salmon, analyst at New Street, reiterates coverage on [Reddit, Inc. (RDDT)]( in the Communication Services sector with a Hold rating and a price target of $54 (6 days ago). Here are 3rd party ratings for [RDDT](: - TipRanks.com: Hold - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: n/a - Zacks.com: n/a, n/a [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [#1 Stock for Energy Crisis (Buy Now for Just $8)]( the world suffers an oil shock… And gas prices rip higher… One tiny company could have the answer to the global energy crisis. It’s using AI to crack open the largest untapped energy source on the planet… 5X larger than the biggest oil field on Earth. [Act fast, this $8 stock could be moments away from appreciating considerably.]( --------------------------------------------------------------- [Gain Therapeutics, Inc.]( Ticker: [GANX]( Recent Price: $3.83 Average Analyst Price Target: $9.00 (134.99%) Market Cap: $62.12M Role Transaction Description No. of Shares Amount Date Director Informative Buy Non Open Market Buy 30,150 $115,500 Yesterday Recent Analyst Action: Ram Selvaraju, analyst at H.C. Wainwright, reiterates coverage on [Gain Therapeutics, Inc. (GANX)]( in the Healthcare sector with a Buy rating and a price target of $9 (22 hours ago). Here are 3rd party ratings for [GANX](: - TipRanks.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Top 37% (93 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Alto Neuroscience, Inc.]( Ticker: [ANRO]( Recent Price: $14.56 Average Analyst Price Target: $32.33 (122.07%) Market Cap: $389.92M Role Transaction Description No. of Shares Amount Date CFO Informative Buy Non Open Market Buy 6,150 $100,628 Yesterday Recent Analyst Action: Ritu Baral, analyst at TD Cowen, reiterates coverage on [Alto Neuroscience, Inc. (ANRO)]( in the Healthcare sector with a Buy rating (1 week ago). Here are 3rd party ratings for [ANRO](: - TipRanks.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: n/a - Zacks.com: Hold, Top 31% (78 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Best way to buy gold today (not what you'd think)]( so many strange events happening across the economy (longest bear market for bonds since Civil War... unprecedented bank closures... and soaring prices) – it's no wonder the richest investors are loading up on gold. But what you might not realize is there's a much better way to profit from rising gold prices – without ever touching an ETF, mining stock, or even bullion. [Full details here.]( --------------------------------------------------------------- [Gray Television, Inc.]( Ticker: [GTN]( Recent Price: $6.02 Average Analyst Price Target: $11.63 (93.11%) Market Cap: $604.62M Role Transaction Description No. of Shares Amount Date COB, Pres & CEO, Director Informative Buy Non Open Market Buy 13,400 $80,900 2 Days Ago Director Informative Buy Non Open Market Buy 13,400 $80,900 2 Days Ago Recent Analyst Action: James Goss, analyst at Barrington, reiterates coverage on [Gray Television, Inc. (GTN)]( in the Communication Services sector with a Hold rating (1 month ago). Here are 3rd party ratings for [GTN](: - TipRanks.com: Hold - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Bottom 15% (214 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Oncternal Therapeutics, Inc.]( Ticker: [ONCT]( Recent Price: $9.30 Average Analyst Price Target: $27.00 (190.32%) Market Cap: $27.52M Role Transaction Description No. of Shares Amount Date Director Informative Buy Non Open Market Buy 6,290 $58,562 2 Days Ago Recent Analyst Action: Carl Byrnes, analyst at Northland Securities, reiterates coverage on [Oncternal Therapeutics, Inc. (ONCT)]( in the Healthcare sector with a Buy rating and a price target of $25 (3 weeks ago). Here are 3rd party ratings for [ONCT](: - TipRanks.com: Hold - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Sell, Top 37% (93 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [AI Discovers $22 Trillion Gold Mine (Video)]( of Silicon Valley’s most secretive billionaires have made a world-changing AI discovery. It places them at the center of a $22.1 trillion boom. And they’re giving everyday investors the chance to join them. A 40-year AI pioneer projects this firm’s valuation could soar 5,000% within a decade. [(Full story…)]( --------------------------------------------------------------- [HilleVax, Inc.]( Ticker: [HLVX]( Recent Price: $15.93 Average Analyst Price Target: $29.80 (87.07%) Market Cap: $791.73M Role Transaction Description No. of Shares Amount Date COO Informative Buy Non Open Market Buy 1,330 $21,225 2 Days Ago Recent Analyst Action: Stephen Willey, analyst at Stifel Nicolaus, reiterates coverage on [HilleVax, Inc. (HLVX)]( in the Healthcare sector with a Buy rating and a price target of $34 (1 week ago). Here are 3rd party ratings for [HLVX](: - TipRanks.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Top 31% (78 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Entrada Therapeutics, Inc.]( Ticker: [TRDA]( Recent Price: $13.76 Average Analyst Price Target: $21.00 (52.62%) Market Cap: $462.35M Role Transaction Description No. of Shares Amount Date Director Informative Buy Non Open Market Buy 9,048 $122,808 7 Days Ago Director Informative Buy Non Open Market Buy 2,732 $34,988 8 Days Ago Recent Analyst Action: Ram Selvaraju, analyst at H.C. Wainwright, reiterates coverage on [Entrada Therapeutics, Inc. (TRDA)]( in the Healthcare sector with a Buy rating and a price target of $20 (2 weeks ago). Here are 3rd party ratings for [TRDA](: - TipRanks.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Strong Sell, Top 31% (78 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Big Pharma's Worst Nightmare Could Make You Rich]( tiny firm’s patented “smart cell” technology could turn the drug industry upside down. [Click here now for details.]( --------------------------------------------------------------- And there you have it. To Your Financial Freedom, The Editor MarketInsidersPress.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be third-party advertisements where the advertiser is paying per click, per lead, or per sale and are not endorsed or warranted by our staff or company. SPMG, AITickers.com and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged not to use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. SPMG, AITickers.com nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from SPMG or AITickers.com to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. This is part of your free subscription to MarketInsidersPress.com MarketInsidersPress.com 1519 Mecklenburg Hwy Unit 4 | Mt. Mourne | NC | 28123 | United States | 877 411 9808 MarketInsidersPress.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mount Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software